The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression
Abstract
BACKGROUND: Immunosuppressive therapy is a risk factor for the increased incidence and metastatic progression of malignancies in organ graft recipients. Transforming growth factor (TGF)-beta(1) has been associated with tumor invasion and metastasis, and we have implicated cyclosporine-associated TGF-beta(1) hyperexpression in tumor progression in mice. METHODS: BALB/c mice or severe combined immunodeficient-beige mice were treated with 2 or 4 mg/kg of tacrolimus, and the effect of treatment on mouse renal cancer cell pulmonary metastasis was investigated. We also determined whether tacrolimus induces TGF-beta(1) expression. Spleens from tacrolimus-treated mice were analyzed for level of expression of TGF-beta(1) mRNA with the use of competitive-quantitative polymerase chain reaction assay, and circulating levels of TGF-beta(1) protein were measured with the use of an enzyme-linked immunosorbent assay. RESULTS: Treatment with tacrolimus resulted in a dose-dependent increase in the number of pulmonary metastases in the BALB/c mice (197+/-16 in untreated mice, 281+/-26 in mice treated with 2 mg/kg of tacrolimus, and 339+/-25 in mice treated with 4 mg/kg of tacrolimus; no treatment vs. 4 mg/kg tacrolimus, Bonferroni's P<0.001) and in the severe combined immunodeficient-beige mice (117+/-18 in untreated mice, 137+/-19 in mice treated with 2 mg/kg of tacrolimus, and 216+/-29 in mice treated with 4 mg/kg of tacrolimus; no treatment vs. 4 mg/kg tacrolimus, P<0.05). Treatment with 4 mg/kg but not 2 mg/kg of tacrolimus resulted in a significant increase in the levels of expression of TGF-beta(1) mRNA and circulating levels of TGF-beta(1) protein. CONCLUSIONS: Tacrolimus has a dose-dependent effect on tumor progression and TGF-beta(1) expression, and tacrolimus-induced TGF-beta(1) overexpression may be a pathogenetic mechanism in tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,149
Self-citationYin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
Post-Transplant Malignancy: The Role Of Immunosuppression
Penn, I. (2000) · Drug Safety · doi:10.2165/00002018-200023020-00002 · Cited by 414
Risk of neoplasia in renal transplant patients
London, N. J., Farmery, S. M., Lodge, J. P. A., Will, E. J., & Davidson, A. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92780-8 · Cited by 396
Wikström, P., Stattin, P., Franck-Lissbrant, I., Damber, J.-E., & Bergh, A. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3 · Cited by 307
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., & Suthanthiran, M. (2002) · Transplantation · doi:10.1097/00007890-200205270-00008 · Cited by 235
Self-citationCalcineurin: Structure, function, and inhibition
Hemenway, C. S., & Heitman, J. (1999) · Cell Biochemistry and Biophysics · doi:10.1007/bf02737887 · Cited by 227
IN VIVO EXPRESSION OF TRANSFORMING GROWTH FACTOR-??1 IN HUMANS: Stimulation by Cyclosporine1
Shin, G.-T., Khanna, A., Ding, R., Sharma, V. K., Lagman, M., Li, B., & Suthanthiran, M. (1998) · Transplantation · doi:10.1097/00007890-199802150-00003 · Cited by 190
Self-citation
Cited by
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 621
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204166 · Cited by 593
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146
Metadata
- Authors
- Maluccio, M., Sharma, V., Lagman, M., Vyas, S., Yang, H., Li, B., & Suthanthiran, M.
- Venue
- Transplantation
- Published
- 2003-08-15
- Volume
- 76
- Issue
- 3
- Pages
- 597-602
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2089265692
- Cited by
- 278
- References
- 18
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. https://app.cochat.ai/papers/10.1097/01.tp.0000081399.75231.3b
- The paper
- Maluccio, M., Sharma, V., Lagman, M., Vyas, S., Yang, H., Li, B., & Suthanthiran, M. (2003). Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression. Transplantation. https://doi.org/10.1097/01.tp.0000081399.75231.3b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.